Study Objectives: To determine whether, in patients with large acute myocardial infarction
undergoing primary or rescue angioplasty, the administration of subcutaneous Lenograstim
[recombinant human Granulocyte-Colony Stimulating Factor (rhu G-CSF), Myelostim 34,
Italfarmaco] associated with Myocardial Contrast Echocardiography and the intravenous
infusion of sulphur hexafluoride (Sonovue, Bracco) determines an improvement:
- in regional and global contractile function, myocardial perfusion and infarct size
assessed by cardiovascular magnetic resonance.
- Echocardiographic parameters of LV function
- in the serum profile of inflammatory and mobilizing cytokines and of biomarkers of
myocardial damage and wall stress